Buprenorphine is a semi-synthetic partial opioid agonist derived from thebaine that is widely indicated for the treatment of opioid use disorder and the management of moderate to severe chronic pain. The… Read more














![Chemical structure of rel-(4S,4aS,6R,7R,7aR,12bS)-3-(Cyclopropylmethyl)-9-hydroxy-6-((S)-2-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-13-one (PSY)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1044710-08-8-rel-4S4aS6R7R7aR12bS-3-Cyclopropylmethyl-9-hydroxy-6-S-2-hydroxy-33-dimethylbutan-2-yl-7-methoxy-12345677a-octahydro-4a7-ethano-412-metha.png&w=3840&q=75)
Buprenorphine is a semi-synthetic partial opioid agonist derived from thebaine that is widely indicated for the treatment of opioid use disorder and the management of moderate to severe chronic pain. The Buprenorphine reference standards, metabolites, and impurities listed in this category are critical for pharmaceutical laboratories conducting rigorous analytical testing, method validation, and quality control. Because Buprenorphine is susceptible to degradation pathways such as oxidation, hydrolysis, and photolysis, researchers rely on these high-quality compounds to perform precise impurity profiling and stability studies. By utilizing these structurally characterized standards, laboratories can ensure compliance with pharmacopeial specifications and ICH guidelines, accurately identifying and quantifying degradation products, structural analogs, and other related substances throughout the lifecycle of the drug product.